Chantal Lokhorst

Chantal Lokhorst

Auto-generated profile, based on publicly available information

Chantal Lokhorst

Center for Congenital Heart Diseases, Department of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, The Netherlands (C. Lokhorst, J.M.D., R.M.F.B.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
CLChantal Lokhorst
Chantal Lokhorst
SWSjoukje van der Werf
Sjoukje van der Werf
RBRolf M. F. Berger
Rolf M. F. Berger
JDJohannes M. Douwes
Johannes M. Douwes
Introduction: Currently, risk stratification is the cornerstone of determining treatment strategy for patients with pulmonary arterial hypertension (PAH). Since the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for the diagnosis and treatment of pulmonary hypertension recommended risk assessment, the number of studies reporting risk stratification has considerably increased. This systematic review aims to report and compare the variables and prognostic value of the various risk stratification models for outcome prediction in adult and pediatric PAH.Methods: A systematic search with terms related to PAH, pediatric pulmonary hypertension, and risk stratification was performed through databases PubMed, EMBASE, and Web of Science up to June 8, 2022. Observational studies and clinical trials on risk stratification in adult and pediatric PAH were included, excluding case reports/series, guidelines, and reviews. Risk of bias was assessed using the Prediction model Risk Of Bias Assessment Tool. Data on the variables used in the models and the predictive strength of the models given by c-statistic were extracted from eligible studies.Results: A total of 74 studies were eligible for inclusion, with this review focusing on model development (n = 21), model validation (n = 13), and model enhancement (n = 9). The variables used most often in current risk stratification models were the non-invasive WHO functional class, 6-minute walk distance and BNP/NT-proBNP, and the invasive mean right atrial pressure, cardiac index and mixed venous oxygen saturation. C-statistics of current risk stratification models range from 0.56 to 0.83 in adults and from 0.69 to 0.78 in children (only two studies available). Risk stratification models focusing solely on echocardiographic parameters or biomarkers have also been reported.Conclusion: Studies reporting risk stratification in pediatric PAH are scarce. This systematic review provides an overview of current data on risk stratification models and its value for guiding treatment strategies in PAH.Systematic review registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022316885], identifier [CRD42022316885].

2 July 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
CLChantal Lokhorst
Chantal Lokhorst
SWSjoukje van der Werf
Sjoukje van der Werf
RBRolf M.F. Berger
Rolf M.F. Berger
JDJohannes Menno Douwes
Johannes Menno Douwes
Background: In pulmonary arterial hypertension, it is recommended to base therapeutic decisions on risk stratification. This systematic review aims to report the prognostic value of serial risk stratification in adult and pediatric pulmonary arterial hypertension and to explore the usability of serial risk stratification as treatment target. Methods and Results: Electronic databases PubMed, Embase, and Web of Science were searched up to January 30, 2023, using terms associated with pulmonary arterial hypertension, pediatric pulmonary hypertension, and risk stratification. Observational studies and clinical trials describing risk stratification at both baseline and follow‐up were included. Sixty five studies were eligible for inclusion, including only 2 studies in a pediatric population. C‐statistic range at baseline was 0.31 to 0.77 and improved to 0.30 to 0.91 at follow‐up. In 53% of patients, risk status changed (42% improved, 12% worsened) over 168 days (interquartile range, 137–327 days; n=22 studies). The average proportion of low‐risk patients increased from 18% at baseline to 36% at a median follow‐up of 244 days (interquartile range, 140–365 days; n=40 studies). In placebo‐controlled drug studies, risk statuses of the intervention groups improved more and worsened less compared with the placebo groups. Furthermore, a low‐risk status, but also an improved risk status, at follow‐up was associated with a better outcome. Similar results were found in the 2 pediatric studies. Conclusions: Follow‐up risk stratification has improved prognostic value compared with baseline risk stratification, and change in risk status between baseline and follow‐up corresponded to a change in survival. These data support the use of serial risk stratification as treatment target in pulmonary arterial hypertension.

8 February 2025 in Chest
Verified
Journal Article
Open access
MPMark-Jan Ploegstra
Mark-Jan Ploegstra
RFRosaria J. Ferreira
Rosaria J. Ferreira
CLChantal Lokhorst
Chantal Lokhorst
EGEva Gouwy
Eva Gouwy
SSSuzanne S.J. Schwartz
Suzanne S.J. Schwartz
RBRolf M.F. Berger
Rolf M.F. Berger
Pediatric pulmonary hypertension (PH) is a severe incurable disease with poor prognosis. In pediatric PH, trial design is hampered by the absence of age-appropriate trial endpoints. This study evaluated physical activity (PA) measured by hip-anchored accelerometry as a potential trial endpoint in pediatric PH. Is PA-accelerometry associated with disease severity, and based on this association, what minimal important differences (MIDs) correspond to meaningful changes in disease severity in pediatric PH? Accelerometer outputs from 54 children with hemodynamically confirmed PH were analyzed. Univariable linear regression and mixed effect models were respectively used for cross sectional and longitudinal analyses 1) to evaluate the association between Z-scores of PA-accelerometry counts per minute (CPM-Z) and of % of time spent in moderate or vigorous physical activity (%MVPA-Z) and disease severity indices 6-minute walk-distance Z-scores (6MWD-Z), World Health Organization functional class (WHO-FC), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and tricuspid annular plane systolic excursion Z-scores (TAPSE-Z) and 2) to perform anchor-based MID estimations for CPM-Z and %MVPA-Z, using defined clinical functional impairment levels (6MWD-Z and WHO-FC) as reference anchors. When assessing the association between disease severity and PA-accelerometry cross-sectionally, we found significant associations between CPM-Z and WHO-FC, 6MWD-Z and NT-proBNP. %MVPA-Z was significantly associated with WHO-FC and 6MWD-Z. In longitudinal analysis, these associations were confirmed throughout the disease course. MID estimations, expressed in Z-score units, resulted in mean MIDs of 0.3-0.4 CPM-Z when anchored to 6MWD-Z, 0.7 CPM-Z when anchored to WHO-FC, 0.4-0.5 %MVPA-Z when anchored to 6MWD-Z and 0.5-0.6 %MVPA-Z when anchored to WHO-FC. This study underscores the robust relationship between PA-accelerometry and disease severity in children with PH and fills a critical gap in pediatric PH trial design and evaluation of treatment efficacy by providing anchor-based MID-estimates for hip-anchored PA-accelerometry.

24 September 2024 in Children
Verified
Journal Article
Open access
PDF file
FSFaye E. Smits
Faye E. Smits
CLChantal Lokhorst
Chantal Lokhorst
MHMeindina G. Haarman
Meindina G. Haarman
MPMark-Jan Ploegstra
Mark-Jan Ploegstra
RBRolf M.F. Berger
Rolf M.F. Berger
JDJohannes Menno Douwes
Johannes Menno Douwes
Background/Objectives: The pulmonary artery pulsatility index (PAPi, calculated as (SPAP − DPAP)/mRAP) has been suggested as a measure of right ventricular–vascular coupling (RVVC) and as a prognostic parameter in cardiovascular conditions, particularly right ventricular failure. This retrospective study investigated the relationship between the PAPi and its components with disease severity parameters, the RVVC, and clinical outcomes in children with pulmonary arterial hypertension (PAH). Methods: We analyzed data from 111 children from the Dutch National Registry with PAH. The PAPi (median 6.0 [3.9–8.3]) was calculated from heart catheterization data and the RVVC was determined as the TAPSE/sPAP ratio via echocardiography (0.25 ± 0.12 mm/mmHg). Disease severity was characterized by clinical, hemodynamic, and laboratory data. Cox proportional hazard modeling assessed the PAPi’s predictive value for transplant-free survival. Results: There was no correlation between the RVVC and PAPi (R = −0.208, p = 0.111, n = 60). The PAPi correlated negatively with uric acid (R = −0.387, p < 0.001) but not with other disease severity parameters. Mean right atrial pressure correlated with multiple disease severity indicators. Transplant-free survival rates at 1, 3, and 5 years were 87%, 79%, and 73%, respectively. Neither the PAPi nor its components correlated with transplant-free survival. Conclusions: In conclusion, the PAPi does not correlate with the RVVC and this study could not demonstrate any prognostic value of the PAPi regarding disease severity or outcomes in children with PAH, challenging its utility in this population.

1 September 2026 in Circulation
Verified
Journal Article
Closed access
Megan GriffithsMegan Griffiths
Megan Griffiths
BCBhargava K. Chinni
Bhargava K. Chinni
CLChantal Lokhorst
Chantal Lokhorst
JDJohannes Menno Douwes
Johannes Menno Douwes
LSLynn A. Sleeper
Lynn A. Sleeper
AEAllen D. Everett
Allen D. Everett
BACKGROUND: Risk prediction is fundamental to pulmonary hypertension (PH) guideline-based care, yet pediatric-specific risk prediction models remain limited, relying primarily on single predictors, expert opinion, or application of adult models to children. The authors developed and externally validated a data-driven 1-year risk prediction model for pediatric PH. METHODS: Pediatric patients with PH (n=345; World Symposium on Pulmonary Hypertension groups 1 and 3) enrolled in the Pediatric Pulmonary Hypertension Network Registry (2014–2020; 50.4% male; median age, 4.9 years [interquartile range, 1.9–10.3]) were split into training (80%) and test cohorts (20%). The Dutch National Registry for Pulmonary Hypertension in Childhood (n=155 [1993–2020]) and the Spanish Registry of Pediatric Pulmonary Hypertension (n=327 [2009–2023]) were used for external validation. From 176 variables, BorutaSHAP feature selection with random forest identified 16 predictors for a 1-year outcome of time to death, transplant, Potts shunt, or atrial septostomy, modeled using extreme gradient boosting. Performance was assessed with the area under the receiver operating characteristic curve, confusion matrices, calibration, and Kaplan-Meier event-free survival. RESULTS: The final model achieved an area under the receiver operating characteristic curve of 0.90 (0.79–0.97) and 99% (96%–99%) negative predictive value in testing, dividing participants into 3 groups with strong outcome discrimination. External validation showed an area under the receiver operating characteristic curve of 0.76 (Dutch National Registry for Pulmonary Hypertension in Childhood, 0.70–0.81) and 0.77 (Spanish Registry of Pediatric Pulmonary Hypertension, 0.73–0.82) with negative predictive values of 93% (93%–97%) and 96% (93%–97%), respectively. Kaplan-Meier analysis significantly differentiated outcomes by risk group. CONCLUSIONS: This multicenter, validated model provides good 1-year risk prediction in pediatric PH across World Symposium on Pulmonary Hypertension groups 1 and 3, providing a robust tool for clinical risk stratification to guide therapy and addressing a gap in pediatric PH care.